Robeco Institutional Asset Management B.V. Increases Stake in Amgen Inc. $AMGN

Key Points

• Robeco Institutional Asset Management raised its stake in Amgen by 10.0% in Q4, buying 43,884 shares to hold 481,453 shares worth about $157.6 million (0.09% of the company).
• Amgen beat Q results with $5.29 EPS (vs. $4.76 est.) and $9.87B revenue, gave FY2026 EPS guidance of 21.60–23.00, and analysts project roughly 20.62 EPS for the current year.
• The company announced a quarterly dividend of $2.52 per share (annualized $10.08, yield ~2.9%), while analyst views are mixed—several target increases but a consensus rating of Hold and an average target price of $355.84.

Robeco Institutional Asset Management B.V. grew its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 10.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 481,453 shares of the medical research company's stock after buying an additional 43,884 shares during the quarter. Robeco Institutional Asset Management B.V. owned 0.09% of Amgen worth $157,584,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Amgen by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 53,876,851 shares of the medical research company's stock worth $15,204,047,000 after buying an additional 165,281 shares during the last quarter. Capital International Investors raised its position in Amgen by 1.5% during the 3rd quarter. Capital International Investors now owns 19,192,995 shares of the medical research company's stock worth $5,414,296,000 after buying an additional 282,219 shares during the last quarter. Capital World Investors increased its holdings in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company's stock valued at $5,303,578,000 after purchasing an additional 1,935,876 shares in the last quarter. Capital Research Global Investors increased its holdings in shares of Amgen by 2.7% in the 3rd quarter. Capital Research Global Investors now owns 4,731,290 shares of the medical research company's stock valued at $1,335,168,000 after purchasing an additional 122,631 shares in the last quarter. Finally, Invesco Ltd. increased its holdings in shares of Amgen by 6.6% in the 3rd quarter. Invesco Ltd. now owns 4,467,287 shares of the medical research company's stock valued at $1,260,668,000 after purchasing an additional 277,031 shares in the last quarter. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $350.92 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. The firm has a 50-day moving average price of $363.87 and a two-hundred day moving average price of $335.08. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $391.29. The company has a market capitalization of $189.39 billion, a P/E ratio of 24.66, a price-to-earnings-growth ratio of 3.48 and a beta of 0.47.

Amgen (NASDAQ:AMGN - Get Free Report) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. During the same period last year, the firm posted $5.31 EPS. The firm's revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be issued a dividend of $2.52 per share. This represents a $10.08 annualized dividend and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen's dividend payout ratio (DPR) is 70.84%.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: China approval for tarlatamab expands Amgen’s lung-cancer market access and supports future revenue in a large oncology market — a meaningful commercial win for a new oncology asset. Amgen's lung cancer drug tarlatamab wins China approval
• Positive Sentiment: Phase‑4 FORWARD II gout study update: a less‑frequent Krystexxa dosing schedule could improve patient adherence and lifetime drug value, which would be positive for product uptake and revenue stability. Amgen’s FORWARD II Gout Study
• Positive Sentiment: Analyst bullishness on fundamentals: Zacks argues Amgen is poised to beat earnings again, supported by its recent history of surprise results and solid guidance — this can underpin near‑term sentiment ahead of the next report. Why Amgen (AMGN) is Poised to Beat Earnings Estimates Again
• Positive Sentiment: Royal Bank of Canada raised its price target to $370, signaling upside from some institutional analysts and suggesting conviction in Amgen’s mid‑term growth drivers. Royal Bank Of Canada Increases Amgen Price Target
• Neutral Sentiment: Guggenheim nudged its target to $351 while retaining a neutral rating — little immediate directional impact given the price is near that level. Amgen Price Target Raised to $351 at Guggenheim
• Neutral Sentiment: Short‑interest data reported for April appears inconsistent/erroneous (reads as 0 shares / NaN increase), so it’s unlikely to be a reliable driver of today’s action. (data entry)
• Neutral Sentiment: Media pieces highlighting Amgen’s profitability and recent TEPEZZA subcutaneous Phase‑3 topline results reinforce the company’s longer‑term value story but are incremental to near‑term price moves. Is Amgen One of the Most Profitable Value Stocks?
• Negative Sentiment: Morgan Stanley’s latest stance (equal‑weight, target raised only to $326) and other hold ratings emphasize limited near‑term upside vs. current levels — that analyst positioning is weighing on the stock. Morgan Stanley equal weight on Amgen

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Wall Street Zen upgraded shares of Amgen from a "hold" rating to a "buy" rating in a report on Saturday. Citigroup increased their price target on shares of Amgen from $315.00 to $345.00 and gave the company a "neutral" rating in a report on Wednesday, February 4th. Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They issued a "hold" rating and a $350.00 price target for the company. Royal Bank Of Canada increased their price target on shares of Amgen from $360.00 to $370.00 and gave the company an "outperform" rating in a report on Tuesday, April 7th. Finally, Freedom Capital downgraded shares of Amgen from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 12th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $355.84.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.